rimabotulinumtoxinB

Known as: rimabotulinumtoxinB [Chemical/Ingredient], rimabotulinumtoxin B, botulinum neurotoxin B 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1997-2018
024619972018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
OBJECTIVE To update the 2008 American Academy of Neurology (AAN) guidelines regarding botulinum neurotoxin for blepharospasm… (More)
Is this relevant?
2015
2015
OBJECTIVES To investigate efficacy, saliva flow, and composition in repeated BoNT-B treatments of drooling. MATERIALS AND… (More)
Is this relevant?
2014
2014
We addressed the hypothesis that intraplantar botulinum toxin B (rimabotulinumtoxin B: BoNT-B) has an early local effect upon… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2013
2013
BACKGROUND Masseter hypertrophy can be ameliorated by botulinum toxin. OBJECTIVE To compare the efficacy and safety of… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2013
2013
BACKGROUND Optimum dose ratios of rimabotulinumtoxinB (BTX-B) and onabotulinumtoxinA (BTX-A) have not been determined for… (More)
Is this relevant?
2013
2013
OBJECTIVE To report a retrospective analysis of patients with migraine headaches treated with rimabotulinumtoxin B as preventive… (More)
Is this relevant?
2012
2012
Botulinum neurotoxins (BoNTs) inhibit neurotransmitter release by hydrolysing SNARE proteins essential for exocytosis. The… (More)
Is this relevant?
2010
2010
Response rate (RR) and mean improvement (MI) in the pain subscale of the Toronto Western Spasmodic Torticollis Rating Scale… (More)
Is this relevant?
2003
2003
Botulinum toxin type B was studied for the management of hyperkinetic facial lines. It showed clinical longevity of up to 12… (More)
Is this relevant?
1997
1997
We enrolled and treated 122 patients with idiopathic cervical dystonia in a double-blind, placebo-controlled safety and efficacy… (More)
Is this relevant?